ARS Pharmaceuticals (SPRY) Free Cash Flow (2020 - 2026)

ARS Pharmaceuticals has disclosed Free Cash Flow across 7 years of filings, most recently posting -$44.9 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$44.9 million, down 10.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$175.3 million (down 732.67% YoY), and the FY2025 annual result was -$171.2 million, down 1418.48% from the prior year.
• Free Cash Flow came in at -$44.9 million for Q1 2026 at ARS Pharmaceuticals, down from -$43.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $41.5 million in Q4 2024 to a low of -$45.4 million in Q2 2025.
• The 5-year median for Free Cash Flow is -$14.6 million (2024), against an average of -$17.8 million.
• Across the five-year window, Free Cash Flow surged 337.45% in 2024 and plunged 530.36% in 2025, its largest moves.
• ARS Pharmaceuticals' Free Cash Flow stood at -$20.5 million in 2022, then grew by 14.75% to -$17.5 million in 2023, then jumped by 337.45% to $41.5 million in 2024, then sank by 204.71% to -$43.5 million in 2025, then slipped by 3.36% to -$44.9 million in 2026.
• The last three Free Cash Flow figures came in at -$44.9 million (Q1 2026), -$43.5 million (Q4 2025), and -$41.5 million (Q3 2025), per Business Quant data.